Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti ...

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, ...

Channel partners have mixed views about the slight delay in Exchange 2003 but have even bigger questions about Kodiak, the next version beyond Exchange 2003. At Tech Ed, Microsoft executives said ...